Seoul Economic Daily EnglishCodex · 实盘不做把握 5/10
北京时间·🕒 发布 07:45:44(首尔 08:45)·⟳ 抓取 08:13:25 +27m41s·⚡ 决策 08-21 10:13:17 +1h59m·67.4 天前
Celltrion在日本推出Steqeyma静脉注射版并新增克罗恩病适应症
事件方向偏正面：IV+SC剂型补齐后可进入克罗恩病诱导治疗场景，提升Steqeyma在日本ustekinumab生物类似药竞争力。
📄 原文Seoul Economic Daily English↗ 原文
Celltrion Launches IV Version of Steqeyma in Japan for Autoimmune Push
Celltrion (068270.KS) has launched an intravenous (IV) version of Steqeyma, an autoimmune disease treatment whose activ…
不做 Celltrion（068270.KS）
不做Celltrion（068270.KS）：事件偏正面但核心审批与适应症扩展4月已公开，8月只是上市落地且未披露销售目标或订单金额，对约46万亿韩元市值的短线预期差不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Celltrion已在4月披露日本厚生劳动省批准Steqeyma IV剂型，并新增克罗恩病适应症；说明本次8月消息不是首次披露核心监管事实。
- 行业媒体同日记录日本IV版获批及SC版上市背景，进一步证明审批事实已公开传播。
- 本次信号报道的是日本IV版正式上市，并强调Celltrion利用既有日本销售网络推广。
关键理由
- 事件方向偏正面：IV+SC剂型补齐后可进入克罗恩病诱导治疗场景，提升Steqeyma在日本ustekinumab生物类似药竞争力。
- 但这不是全新审批，4月日本获批已公开，8月上市更接近既定商业化推进，对Celltrion约46万亿韩元市值的短线增量难以量化。
- 量级上，公开材料未披露日本Steqeyma目标销售额或订单金额；即使日本Remsima/Yuflyma份额较高，本事件仍缺少可直接映射到收入或利润的新增数字。
主要风险
- 核心风险是4月获批信息已提前传播，当前只是本地上市落地，预期差不足。
- 未披露日本ustekinumab市场规模、定价、渗透率和Celltrion经济权益，无法给出可靠业绩增量测算。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-04-21 · 影响 weakens
核心审批和适应症扩展已在4月公开，削弱8月上市报道的新鲜度和预期差。
检索:Celltrion Steqeyma Japan IV approval April 2026 already approved 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-04-21 · 影响 weakens
日本ustekinumab生物类似药已有Alvotech/Fuji、Biocon/Yoshindo、Samsung Bioepis等竞品，Celltrion虽有双剂型优势但并非无竞争格局。
检索:Celltrion Steqeyma Japan biosimilar competitors Alvotech Biocon Samsung Bioepis 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加金额未披露和审批旧闻，最终压低置信度并选择不交易。
方向:未找到足够高相似、同市场、同相位的日本生物类似药上市先例来校准短线收益。
涨幅量级:缺少可用event_study样本，不能用历史涨幅支持ENTER。
形态:审批后数月的商业化上市通常更接近预期兑现，存在见光死或无反应风险，但本轮未能用足够先例量化。
原文全文
展开原文 · 2,054 字
Celltrion (068270.KS) has launched an intravenous (IV) version of Steqeyma, an autoimmune disease treatment whose active ingredient is ustekinumab, in Japan, stepping up its push into the local market.
Celltrion said on the 21st that it completed the local launch about four months after obtaining product approval for the IV version of Steqeyma from Japan's Ministry of Health, Labour and Welfare (MHLW) in April. The company also expanded the drug's scope of treatment by adding Crohn's disease (CD) to its existing indications for psoriasis (PsO) and psoriatic arthritis (PsA).
Celltrion's Japan unit plans to use the sales channels and medical networks it built through sales of Remsima (infliximab) and Yuflyma (adalimumab) to establish Steqeyma in the market. As of May this year, Remsima and Yuflyma held Japanese market shares of 46.9% and 19.5%, respectively, ranking first in biosimilar prescriptions.
Having both IV and subcutaneous (SC) versions is also cited as a competitive advantage. Patients can receive initial treatment through induction therapy using the IV version, then manage the disease over the long term through maintenance therapy using the SC version. Among ustekinumab biosimilars currently on the market in Japan, Steqeyma is the only product with both IV and SC versions.
In the second half of the year, Celltrion plans to promote Steqeyma's competitiveness at major conferences such as Japan Digestive Disease Week (JDDW) and the Japanese Society for Inflammatory Bowel Disease (JSIBD) to expand prescriptions. The company also intends to use the network it has built with medical staff and pharmacists as a sales base for Remsima SC, which is scheduled to launch next year.
"With the launch of the IV version of Steqeyma, we have secured both versions and gained a differentiated strength over competitors," a Celltrion official said. "We will use the network built through sales of our existing products to lead Steqeyma's early establishment in the market and expand our influence in Japan's autoimmune disease market."
Celltrion said on the 21st that it completed the local launch about four months after obtaining product approval for the IV version of Steqeyma from Japan's Ministry of Health, Labour and Welfare (MHLW) in April. The company also expanded the drug's scope of treatment by adding Crohn's disease (CD) to its existing indications for psoriasis (PsO) and psoriatic arthritis (PsA).
Celltrion's Japan unit plans to use the sales channels and medical networks it built through sales of Remsima (infliximab) and Yuflyma (adalimumab) to establish Steqeyma in the market. As of May this year, Remsima and Yuflyma held Japanese market shares of 46.9% and 19.5%, respectively, ranking first in biosimilar prescriptions.
Having both IV and subcutaneous (SC) versions is also cited as a competitive advantage. Patients can receive initial treatment through induction therapy using the IV version, then manage the disease over the long term through maintenance therapy using the SC version. Among ustekinumab biosimilars currently on the market in Japan, Steqeyma is the only product with both IV and SC versions.
In the second half of the year, Celltrion plans to promote Steqeyma's competitiveness at major conferences such as Japan Digestive Disease Week (JDDW) and the Japanese Society for Inflammatory Bowel Disease (JSIBD) to expand prescriptions. The company also intends to use the network it has built with medical staff and pharmacists as a sales base for Remsima SC, which is scheduled to launch next year.
"With the launch of the IV version of Steqeyma, we have secured both versions and gained a differentiated strength over competitors," a Celltrion official said. "We will use the network built through sales of our existing products to lead Steqeyma's early establishment in the market and expand our influence in Japan's autoimmune disease market."
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。